Events Partner Content Joint 23rd Medicines for Europe – 20th IGBA Annual Conferenc... The Joint 23rd Medicines for Europe – 20th IGBA Annual Conference will unite over 300 experts from the generic and biosimilar sectors to discuss market trends, innovative comm
News Waiting on NICE decision, Pfizer provides breast cancer drug... NICE rejected Ibrance in initial decision in February.
News NICE backs Amgen's Blincyto in rare leukaemia Drug will also be available to children via Cancer Drugs Fund.
News Government wasted £1.3 billion on Cancer Drugs Fund, says st... The £1.3 billion of public expenditure on the old Cancer Drugs Fund (CDF) did not deliver value to patients or society, according to a new study.
News UK pharma calls for increased NHS funding ahead of election NHS funding at heart of pharma's election manifesto.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.